Julie S. Lau

TL;DR: It is reported here that constitutive or inducible expression of B7-H1, a B7 family molecule widely expressed by cancers, confers resistance to therapeutic anti-CD137 antibody in mice with established tumors and implicate new approaches for immunotherapy of human cancers.

TL;DR: A newly identified member of the human B7 family, designated B7 homolog 3 (B7-H3), that shares 20–27% amino acid identity with other B7family members is described, that may participate in the regulation of cell-mediated immune responses.

TL;DR: A stepwise development of a nanoparticle-based targeted delivery system for in vitro and in vivo therapeutic application in pancreatic cancer and it is confirmed that the inhibition of tumor growth was due to targeted delivery.

TL;DR: The data indicate that homologous recombination by gene conversion does not depend on 53BP1, and mice deficient in the tumor suppressors ATM and H2AX support normal V(D)J recombination, indicating that 53 BP1 is not required for “classic” nonhomologous end joining.

TL;DR: It is reported that the genomic DNA of human B7-H4 is mapped on chromosome 1 comprised of six exons and five introns spanning 66 kb, of which exon 6 is used for alternative splicing to generate two different transcripts.